METTL3 and nonpapillary renal cell carcinoma: These observations imply that METTL3-mediated m6A methylation of NEAT1 may suppress NEAT1 expression, acting as a critical regulator of tumorigenesis and progression, and highlighting its potential as a therapeutic target for ccRCC treatment (Figures 1, 2; Table 1).